D.E. Shaw & Co’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-305,279
| Closed | -$3.42M | – | 3893 |
|
|
2017
Q3 | $3.42M | Buy |
305,279
+19,132
| +7% | +$211K | 0.01% | 1661 |
|
|
2017
Q2 | $3.15M | Buy |
286,147
+10,419
| +4% | +$104K | 0.01% | 1681 |
|
|
2017
Q1 | $2.7M | Sell |
275,728
-15,957
| -5% | -$159K | ﹤0.01% | 1658 |
|
|
2016
Q4 | $3.15M | Sell |
291,685
-14,408
| -5% | -$144K | 0.01% | 1665 |
|
|
2016
Q3 | $3.14M | Sell |
306,093
-153,326
| -33% | -$1.67M | 0.01% | 1600 |
|
|
2016
Q2 | $6M | Sell |
459,419
-233,255
| -34% | -$3.06M | 0.01% | 1172 |
|
|
2016
Q1 | $7.62M | Buy |
692,674
+49,285
| +8% | +$438K | 0.01% | 1008 |
|
|
2015
Q4 | $5.92M | Buy |
643,389
+240,441
| +60% | +$2.01M | 0.01% | 1284 |
|
|
2015
Q3 | $2.8M | Buy |
402,948
+168,886
| +72% | +$1.45M | ﹤0.01% | 1841 |
|
|
2015
Q2 | $2.3M | Sell |
234,062
-22,619
| -9% | -$206K | ﹤0.01% | 2078 |
|
|
2015
Q1 | $2.27M | Sell |
256,681
-65,658
| -20% | -$523K | ﹤0.01% | 1904 |
|
|
2014
Q4 | $2.82M | Buy |
322,339
+126,937
| +65% | +$1.03M | ﹤0.01% | 1988 |
|
|
2014
Q3 | $1.35M | Buy |
195,402
+98,431
| +102% | +$590K | ﹤0.01% | 2563 |
|
|
2014
Q2 | $510K | Sell |
96,971
-43,992
| -31% | -$214K | ﹤0.01% | 3517 |
|
|
2014
Q1 | $641K | Sell |
140,963
-60,502
| -30% | -$292K | ﹤0.01% | 3395 |
|
|
2013
Q4 | $1.01M | Buy |
201,465
+99,021
| +97% | +$477K | ﹤0.01% | 3152 |
|
|
2013
Q3 | $519K | Sell |
102,444
-29,506
| -22% | -$164K | ﹤0.01% | 3556 |
|
|
2013
Q2 | $654K | Buy |
+131,950
| New | +$628K | ﹤0.01% | 3044 |
|
D.E. Shaw & Co's SCLN Position: Q4 2017 in Review
D.E. Shaw & Co sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 305,279 shares — an estimated $3.42M sold.
D.E. Shaw & Co first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $7.62M in Q1 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- D.E. Shaw & Co reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- D.E. Shaw & Co sold 305,279 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $3.42M.
- D.E. Shaw & Co first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- D.E. Shaw & Co's Sciclone Pharmaceuticals Inc position peaked at $7.62M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on D.E. Shaw & Co's 13F filing for Q4 2017, filed 14 Feb 2018.